论文部分内容阅读
预测并合成survivin-△Ex3 HLA-A2.1限制性CTL表位的基因疫苗,探讨携带表位基因的减毒鼠伤寒沙门氏菌口服疫苗对小鼠移植肝癌模型的保护作用。将表位基因序列连接,构建pVAX1-STEsEGFP真核表达载体,转化入减毒鼠伤寒沙门氏菌作为口服疫苗。实验动物分为未免疫对照组、口服沙门氏菌组、pVAX1质粒转染的减毒鼠伤寒沙门氏菌组;口服pVAX1-Survivin-△3(T34A)–EGFP质粒转染的的减毒鼠伤寒沙门氏菌组和口服pVAX1-STEs–EGFP质粒转染的的减毒鼠伤寒沙门氏菌组。结果表明:在5组肿瘤模型小鼠中,肿瘤瘤块平均直径分别为:15.11±2.43 mm、13.70±2.97 mm、13.05±1.77 mm、7.46±2.61 mm、9.05±2.18 mm;表位疫苗组与其他组相比,有显著性差异(P<0.01)。说明小鼠口服携带survivin-△Ex3 HLA-A2.1限制性CTL表位的基因疫苗后,能抑制小鼠肝癌细胞的增殖和扩散。
To predict and synthesize the survivin- △ Ex3 HLA-A2.1 restricted CTL epitope gene vaccine to investigate the protective effect of attenuated Salmonella typhimurium oral vaccine carrying the epitope gene on mouse liver transplantation model. The epitope gene sequence was ligated to construct pVAX1-STEsEGFP eukaryotic expression vector and transformed into attenuated Salmonella typhimurium as oral vaccine. The animals were divided into three groups: untreated control group, oral Salmonella group, and attenuated Salmonella typhimurium group transfected with plasmid pVAX1. Salmonella attenuated Salmonella typhimurium group was orally administered with pVAX1-Survivin-△ 3 (T34A) -EGFP plasmid and orally The attenuated Salmonella typhimurium group transfected with pVAX1-STEs-EGFP plasmid. The results showed that the average diameter of the tumor mass was 15.11 ± 2.43 mm, 13.70 ± 2.97 mm, 13.05 ± 1.77 mm, 7.46 ± 2.61 mm and 9.05 ± 2.18 mm in the 5 groups of tumor model mice respectively. Compared with other groups, there was a significant difference (P <0.01). The results showed that oral administration of gene vaccine carrying survivin- △ Ex3 HLA-A2.1 restricted CTL epitope could inhibit the proliferation and proliferation of mouse hepatoma cells.